Abstract
Idiopathic giant cell myocarditis is a rare condition with a poor prognosis. Patients with giant cell myocarditis typically die of refractory ventricular arrhythmias or progressive congestive heart failure in about 3 months. The benefit of immunosuppressive therapy varies among patients with giant cell myocarditis, and no factors that would predict which patients will respond to therapy have been identified. Mechanical circulatory support devices, from intra-aortic balloon pumps to more permanent systems, have been used for ventricular support in cases of acute heart failure. Herein, we describe a case of giant cell myocarditis in a previously healthy 44-year-old woman who presented with cardiogenic shock. She was supported hemodynamically with the Impella Recover LP 2.5 left ventricular assist device until a permanent device could be surgically implanted. To our knowledge, this is the 1st reported case of the successful use of the Impella device for hemodynamic support in a patient with giant cell myocarditis until more definitive treatment could be instituted.
| Original language | English |
|---|---|
| Pages (from-to) | 437-440 |
| Number of pages | 4 |
| Journal | Texas Heart Institute Journal |
| Volume | 38 |
| Issue number | 4 |
| State | Published - 2011 |
Fingerprint
Keywords
- Autoimmune diseases/complications/drug therapy
- Disease progression
- Equipment design
- Giant cells/drug effects/pathology
- Heart failure/immunology/pathology
- Heart-assist devices
- Hemodynamics/physiology
- Left
- Myocarditis/diagnosis/epidemiology/ physiopathology/therapy
- Treatment outcome
- Ventricular dysfunction
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Cite this
Successful use of the impella device in giant cell Myocarditis as a bridge to permanent left Ventricular mechanical support. / Suradi, Hussam; Breall, Jeffrey.
In: Texas Heart Institute Journal, Vol. 38, No. 4, 2011, p. 437-440.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Successful use of the impella device in giant cell Myocarditis as a bridge to permanent left Ventricular mechanical support
AU - Suradi, Hussam
AU - Breall, Jeffrey
PY - 2011
Y1 - 2011
N2 - Idiopathic giant cell myocarditis is a rare condition with a poor prognosis. Patients with giant cell myocarditis typically die of refractory ventricular arrhythmias or progressive congestive heart failure in about 3 months. The benefit of immunosuppressive therapy varies among patients with giant cell myocarditis, and no factors that would predict which patients will respond to therapy have been identified. Mechanical circulatory support devices, from intra-aortic balloon pumps to more permanent systems, have been used for ventricular support in cases of acute heart failure. Herein, we describe a case of giant cell myocarditis in a previously healthy 44-year-old woman who presented with cardiogenic shock. She was supported hemodynamically with the Impella Recover LP 2.5 left ventricular assist device until a permanent device could be surgically implanted. To our knowledge, this is the 1st reported case of the successful use of the Impella device for hemodynamic support in a patient with giant cell myocarditis until more definitive treatment could be instituted.
AB - Idiopathic giant cell myocarditis is a rare condition with a poor prognosis. Patients with giant cell myocarditis typically die of refractory ventricular arrhythmias or progressive congestive heart failure in about 3 months. The benefit of immunosuppressive therapy varies among patients with giant cell myocarditis, and no factors that would predict which patients will respond to therapy have been identified. Mechanical circulatory support devices, from intra-aortic balloon pumps to more permanent systems, have been used for ventricular support in cases of acute heart failure. Herein, we describe a case of giant cell myocarditis in a previously healthy 44-year-old woman who presented with cardiogenic shock. She was supported hemodynamically with the Impella Recover LP 2.5 left ventricular assist device until a permanent device could be surgically implanted. To our knowledge, this is the 1st reported case of the successful use of the Impella device for hemodynamic support in a patient with giant cell myocarditis until more definitive treatment could be instituted.
KW - Autoimmune diseases/complications/drug therapy
KW - Disease progression
KW - Equipment design
KW - Giant cells/drug effects/pathology
KW - Heart failure/immunology/pathology
KW - Heart-assist devices
KW - Hemodynamics/physiology
KW - Left
KW - Myocarditis/diagnosis/epidemiology/ physiopathology/therapy
KW - Treatment outcome
KW - Ventricular dysfunction
UR - http://www.scopus.com/inward/record.url?scp=80051710401&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80051710401&partnerID=8YFLogxK
M3 - Article
C2 - 21841879
AN - SCOPUS:80051710401
VL - 38
SP - 437
EP - 440
JO - Texas Heart Institute Journal
JF - Texas Heart Institute Journal
SN - 0730-2347
IS - 4
ER -